Elixirgen and Nippon Shinyaku ink option agreement on DMD
Source: news.google.com
Published: Jun 26, 2026 13:41
Source: news.google.com
Published: Jun 26, 2026 13:41
Related Stories
Dupilumab Improves Outcomes for EoG in Phase 2 Clinical Trial Research Horizons
#Clinical TrialsBiogen ends Apellis research programs, cuts ‘small number’ of roles after $5.6B buyout Fierce Biotech
#Biotech HeadlinesBIO 2026: Making biotech IPOs great again and the forgotten pharma antitrust review BioSpace
#Biotech HeadlinesEmbryo editing advances reignite ethical debates statnews.com
#Biotech HeadlinesUS to provide new experimental Ebola drug Yahoo
#Clinical Trials“It’s time to Act”: EU biotech to undergo major changes Labiotech.eu
#Biotech HeadlinesAdd Shortcut
Open this site faster like an app from your phone home screen.